📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). (2022)

First Author: James ND

Attributed to: Evaluating new healthcare technologies in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/ijc.34018

PubMed Identifier: 35411939

Publication URI: http://europepmc.org/abstract/MED/35411939

Type: Journal Article/Review

Volume: 151

Parent Publication: International journal of cancer

Issue: 3

ISSN: 0020-7136